|
|
InMed Announces Appointment of Chief Operating Officer
|
Vancouver, BC, July 19, 2022--InMed Pharmaceuticals Inc. (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, announces Michael Woudenberg has been appointed Chief Operating Officer of the Company, overseeing all day-to-day operations.
|
|
|
|
|
InMed Announces Management Changes
|
Vancouver, BC, April 4, 2022--InMed Pharmaceuticals Inc. (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, announces that its Chief Financial Officer, Mr. Bruce Colwill, will be retiring and will be stepping down from his position at the Company effective March 31, 2022.
|
|
|
|
|
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755
|
Vancouver, BC, January 8, 2021--InMed Pharmaceuticals Inc. (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), announced top-line results from its 755-102-HV Phase 1 clinical trial ("Study 102").
|
|
|
|
|
InMed Introduces IntegraSyn: An Integrated Cannabinoid Manufacturing System
|
Vancouver, BC, June 25, 2020--InMed Pharmaceuticals Inc. (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol, introduced details of IntegraSynTM, the Company's new approach to producing pharmaceutical-grade cannabinoids.
|
|
|
|
|
|
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755
|
Vancouver, BC, May 12, 2020--InMed Pharmaceuticals Inc. (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol, announced it has received regulatory and ethics board approval of its Clinical Trial Application to conduct its second Phase 1 trial with INM-755.
|
|
|
|
|
|